基蛋生物(603387) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥403,956,352.10, representing a year-on-year increase of 25.50%[3] - The net profit attributable to shareholders for Q3 2022 was ¥145,399,343.30, reflecting a significant increase of 76.76% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥135,619,425.05, up by 83.96% year-on-year[3] - For the first three quarters of 2022, the company achieved a total revenue of 1.377 billion RMB, representing a year-over-year growth of 49.34%[11] - The net profit attributable to shareholders for the same period was 475 million RMB, an increase of 87.74% compared to the previous year[11] - Net profit for the first three quarters of 2022 was ¥481,071,216.93, representing a 83.5% increase from ¥262,123,493.95 in the same period of 2021[20] - The company reported a total comprehensive income of ¥481,643,628.87 for the third quarter of 2022, compared to ¥262,121,862.08 in the same quarter of 2021[21] Cash Flow and Liquidity - The cash flow from operating activities for the year-to-date period increased by 113.33% to ¥207,880,331.23[3] - The net cash flow from operating activities for Q3 2022 was ¥207,880,331.23, an increase from ¥97,446,913.82 in Q3 2021, representing a growth of approximately 113%[24] - Total cash inflow from operating activities amounted to ¥1,456,238,026.02, compared to ¥1,106,288,768.88 in the previous year, indicating a year-over-year increase of about 32%[24] - Cash outflow from operating activities was ¥1,248,357,694.79, up from ¥1,008,841,855.06, reflecting a rise of approximately 24%[24] - The company’s cash and cash equivalents as of September 30, 2022, amounted to approximately 1.135 billion RMB, up from 968.9 million RMB at the end of 2021[15] - The cash and cash equivalents at the end of the period reached ¥1,133,577,261.76, up from ¥939,447,825.95 at the end of Q3 2021, representing an increase of approximately 21%[25] Assets and Equity - The total assets at the end of the reporting period were ¥3,654,181,309.98, a growth of 16.45% from the end of the previous year[4] - The equity attributable to shareholders at the end of the reporting period was ¥2,458,822,357.52, marking a 16.73% increase year-on-year[4] - Total assets as of September 30, 2022, were approximately 3.654 billion RMB, compared to 3.138 billion RMB at the end of 2021[16] - Total equity reached ¥2,641,369,078.62, up from ¥2,274,029,770.25 in the same period of 2021[18] Research and Development - Research and development investment for the first three quarters reached 170 million RMB, a year-over-year increase of 30.17%[13] - Research and development expenses for the first three quarters of 2022 were ¥151,894,491.01, an increase from ¥119,364,029.14 in the same period of 2021[19] Product Development and Market Strategy - The company attributed the revenue growth to the expansion of its product line and effective control of domestic COVID-19, leading to a significant increase in sales[6] - The company reported a year-to-date net profit growth driven by increased sales of self-produced products and improved cost control[6] - The company plans to launch several new products in Q4 2022, including the fully automated coagulation analyzer CA5200 and the high-speed fully automated chemiluminescence analyzer MAGICL6200[13] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[19] Inventory and Operating Costs - The company’s inventory increased to approximately 376 million RMB, up from 252 million RMB in the previous year[16] - Total operating costs for the first three quarters of 2022 were ¥847,993,776.91, up 30.6% from ¥649,303,464.59 in the previous year[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 37,376[8] - Basic and diluted earnings per share for the third quarter of 2022 were both ¥0.93, compared to ¥0.50 in the same quarter of 2021[21]